Plain-English translation of NCT05739981 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Cancer research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether adding a new immunotherapy drug called to standard ovarian cancer treatment — chemotherapy plus a drug called — works better than standard treatment alone. You would receive the medication weekly during chemotherapy and then continue it during a maintenance phase if your cancer doesn't progress. The goal is to see if this combination helps people with advanced ovarian, fallopian tube, or primary peritoneal cancer live longer and healthier lives.
Currently, standard treatment for advanced ovarian cancer involves chemotherapy and , but outcomes could still be better for many patients. Researchers believe that adding an immunotherapy drug to boost the body's own immune system might help fight the cancer more effectively.
You likely qualify if…
You likely don't qualify if…
You would receive intravenous chemotherapy ( and ) every three weeks for 4–6 cycles before surgery, combined with weekly injections of the new medication starting in the first cycle. After surgery and recovery, you would continue three more cycles of chemotherapy plus the medication, followed by alone or with the medication for up to 18 additional cycles, depending on your treatment group and how well the cancer responds. Throughout the trial, you would have regular clinic visits and tests to monitor your health and how the cancer is responding.
AI-generated summary from trial data · Aug 4, 2026 · Not medical advice
United States